Seelos Therapeutics

Seelos Therapeutics is a publicly traded, clinical-stage biopharmaceutical company focused on the efficient development of therapies for CNS disorders and rare diseases. Founded in 2016, its strategy centers on acquiring and developing a diversified portfolio of assets, including small molecules, psychedelics, and gene therapies, often through repurposing or reformulating known compounds. The company's lead asset, SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB), is in a registration-directed Phase 2 study, representing its most advanced program. Seelos operates as a lean organization, aiming to de-risk development by targeting serious conditions with limited treatment options.

Portfolio-based development strategy focused on repurposing/reformulating known compounds and employing multiple therapeutic modalities (small molecules, psychedelics, gene therapy, peptides) for CNS and rare diseases.

For SLS-002, competition includes Johnson & Johnson's Spravato (for depression, not acute SI) and off-label ketamine, but the primary competitor is the inadequate standard of care. In ALS and Parkinson's, the landscape is highly competitive with numerous large biopharma players, though Seelos's niche mechanisms and trial strategies aim to differentiate.